Upcoming conferences

Evgen Pharma PLC

13 November 2023

 

Evgen Pharma plc

("Evgen" or the "Company")

Attendance at upcoming investor conferences

Alderley Park, UK - 13 November 2023: Evgen Pharma plc (AIM: EVG), a clinical stage drug development 

company developing sulforaphane-based medicines for the treatment of cancer and other indications, notes that members of its executive team will be participating in the following investor events:

·    LSX Inv€$stival Showcase, Monday 13 November 2023, London
Huw Jones (CEO) and Helen Kuhlman (CBO) will be attending, and Huw Jones will be presenting on Stage 4: Biotech Public Stage at 13:45

·    Jefferies London Healthcare Conference, 14-16 November 2023, London
Huw Jones (CEO) and Helen Kuhlman (CBO) will be attending

·    Members of the Evgen Pharma executive team will be attending the JP Morgan Healthcare Conference and Biotech Showcase on 8-11 January 2024 in San Francisco

If you would like to meet the team at any of these events, please contact the Company via email at [e-mail].

Please refer to the conference websites for further information and up to date schedules.

-Ends-

Enquiries:

Evgen Pharma plc Dr Huw Jones, CEO  Toni Hänninen, CFO Dr Helen Kuhlman, CBO	[phone]
Cavendish (Nominated Advisor and Broker) Geoff Nash / Teddy Whiley (Corporate Finance) Nigel Birks (ECM)	[phone]
Instinctif Partners Melanie Toyne-Sewell / Rozi Morris / Jack Kincade		[phone] [e-mail]

About Evgen Pharma plc 

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane. 

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. Recently, Evgen completed an out-licensing transaction with Stalicla SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of $160.5m and a double-digit royalty on sales.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com.

 

END